Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
INdividualized ITI Based on Fviii(ATE) Protection by VWF
NCT03204539 · University of California, Davis · PHASE4 · terminated · last registry update 2020-05-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Termination of funding from sponsor.” | – | Registry record, University of California, Davis |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VWF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-02-18Phase 3 first posted: Bioverativ, a Sanofi company, efanesoctocog alfa (BIVV001) (NCT04759131)
- 2020-12-17Also stopped (withdrawn): City of Hope Medical Center, FVIII Concentrates + FVIII/VWF concentrates (NCT01051544)
- 2020-11-25Phase 3 first posted: Bioverativ, a Sanofi company, efanesoctocog alfa (BIVV001) (NCT04644575)
- 2020-04-14Phase 3 first posted: Nicoletta C Machin, Recombinant Von Willebrand factor + Tranexamic Acid Injection [Cyklokapron] (NCT04344860)
- 2019-12-24Results posted on the registry: Octapharma, Wilate (NCT03376516)
- 2019-12-03Results posted on the registry: Octapharma, Wilate (NCT02954575)
- 2019-12-02Results posted on the registry: Bioverativ, a Sanofi company, Advate (Low Dose) + Advate (High Dose) (NCT03205163)
- 2019-11-13Phase 3 first posted: Bioverativ, a Sanofi company, efanesoctocog alfa (BIVV001) (NCT04161495)
- 2019-08-29Phase 3 first posted: Sanofi, Caplacizumab (ALX-0081) + Plasma exchange (PE) (NCT04074187)
- 2019-08-12Phase 3 first posted: Octapharma, Wilate (NCT04052698)
- 2019-06-11Also stopped (terminated): Margaret Ragni, Neumega (Oprelvekin, Interleukin 11, IL-11) (NCT00524225)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision